FDA clears iSchemaView imaging platform for selecting stroke patients for clot removal
iSchemaView has received FDA clearance for its RAPID neuroimaging platform to be used for selecting stroke patients for endovascular thrombectomy. It is the first imaging platform to receive such approval.
Providers can now use RAPID CT-Perfusion and RAPID MR-Perfusion, two tools included in the RAPID platform, to help them find patients who would benefit the most from such a procedure.
“This FDA clearance confirms RAPID as the de facto standard in neuroimaging, not only for the automated analysis of brain images derived from CT and MRI, but now for the diagnosis and treatment of stroke,” Don Listwin, CEO of iSchemaView, said in a prepared statement. “The new clearance will particularly benefit smaller community hospitals and the patients they serve. Because RAPID enables stroke treatment decisions that are based on intuitive and easily interpretable real-time views of brain perfusion, physicians will quickly and easily be able to determine which patients can be treated locally and which require urgent transfer to thrombectomy centers—bolstering the capabilities of smaller hospitals and therefore improving patient care.”
Back in May 2018, iSchemaView announced that its RAPID CTA solution had gained FDA clearance.
Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.